A Comparative Study of Treatment Toxicities Between FOLFOX 4 and Modified FOLFOX 6 in Iranian Colorectal Cancer Patients
Journal Title: International Journal of Cancer Management - Year 2017, Vol 10, Issue 1
Abstract
Background: Colorectal cancer is one major health problem and cancer-related cause of death in cancer patients in countries such as Iran where the most cases are diagnosed in advanced stages. Objectives: To evaluate the incidence and severity of toxic effects in colorectal cancer patients who have been treated with two different schedules of combination of oxaliplatin and bolus/infusional 5-fluorouracil with leucovorin (FOLFOX) and to compare them. Methods: Medical records of 458 patients with colorectal cancer treated with FOLFOX 4 and modified FOLFOX 6 regimen between 2005 and 2014 were reviewed. Data from 96 eligible patients were analyzed. Fifty-six patients (58.3%) received FOLFOX 4 and 40 patients (41.7%) received modified FOLFOX 6. Results: The study included 96 patients, 39 of whom were males (40.6%) and 57 of whom were females (59.4%). The median age was 62 years (range: 38 - 87 years). The follow up duration was between 16 - 109 months with a median of 62 months. There was a statistically significant incidence rate of grade 1 toxicity of diarrhea as gastrointestinal (GI) toxicity between FOLFOX 4 and modified FOLFOX 6 as the two regimens (P = 0.034), but there was not a statistically significant incidence rate of grade 1 toxicity of stomatitis as GI toxicity between the two regimens (P = 0.27).We observed a highly statistically significant incidence rate of grade 1 toxicity of neutropenia as hematologic toxicity between FOLFOX 4 and modified FOLFOX 6 as the two regimens (P < 0.001), but we did not observe any statistically significant differences of grade 1 of thrombocytopenia as hematologic toxicity between the two regimens (P = 0.063). There was a statistically significant incidence rate of grade 1 neurotoxicity between FOLFOX 4 and modified FOLFOX 6 as the two regimens (P = 0.017). Conclusions: We showed that in colorectal cancer patients treated with modified FOLFOX6. Some of hematological and nonhematological complications were more than FOLFOX4 and they can be concerned.
Authors and Affiliations
Keywords
Related Articles
- EP ID EP237281
- DOI -
- Views 80
- Downloads 0
Seroprevalence of Cytomegalovirus Antibodies and Primary Infection amongWomen and Infants in Iran: A Meta-Analysis
Background: Seroprevalence of Cytomegalovirus infection varies between 40% and 100% worldwide. Different studies carried out in Iran indicate this variation in this country. It is important to estimate the total infectio...
Association Between Cytochrome 1B1*3 Polymorphism and the Breast Cancer in a Group of IranianWomen
Background: As a hormone-dependent cancer, estrogen is involved in the development of breast cancer. CYP1B1 belongs to the P450 superfamily of enzymes and is involved in the metabolism of estrogen. The present study inve...
Evaluation of Anti-Melanogenic and Cytotoxic Activities of <i>Phlomis caucasica</i> on Human Melanoma SKMEL-3 Cells
Background Under normal physiological condition, melanosomal melanin acts as a natural UV photoprotective filter. However, after long exposure to UV radiation, melanin has shown t...
The Effect of Polymorphisms on the Ala 119 Ser Gene Cytochrome P450 1B1*2 on the Susceptibility of Iranian Women to Develop Breast Cancer
Background Cytochrome P450 IBI (CYP1B1) is involved in the metabolism of a wide range of internal and external substrates and also plays a key role in the metabolism of oestrogen....
Postmenopausal Choriocarcinoma: Case Report and Literature Review
Introduction: Choriocarcinoma is a gestational trophoblastic tumor that mainly affects women of childbearing age and rarely occurs in postmenopausal women especially following a long latent period from previous pregnanci...